// App-Quantinova.ai

e21685 : Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based therapies.

Researchers

Presenter

  • Cindy Weinstein

Principal Investigators

  • Karin Jordan

  • Stuart Green

  • Saleem A. Khanani

  • Elizabeth Beckford-Brathwaite

  • Waldimir Vallejos

  • Annpey Pong

  • Stephen Joseph Noga

  • Bernardo Rapoport

Medical Centers

  • Merck & Co., Inc., Kenilworth, NJ

  • Martin-Luther-University Halle-Wittenberg, Halle, Germany

  • Reliant Medical Group, Worcester, MA

  • Weinberg Cancer Institute, Baltimore, MD

  • The Medical Oncology Centre of Rosebank, Johannesburg, South Africa

Locations

  • United States

  • Germany

  • South Africa

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • C-C Motif Chemokine Ligand 28

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Fosaprepitant

  • Ondansetron

  • Carboplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Parallel Group

Phase

  • III

Study Id's

  • NCT01594749

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved